CEACAM5 and neoplasm: Adjusting for the known covariates including sex, age, CEA level, tumor location, operation, tumor grade, and adjuvant chemotherapy, patients with high-monocyte count still showed significantly higher risk of death (HR = 2.55, 95 % CI 1.27–5.10; P = 0.008) and disease (HR = 2.63, 95 % CI 1.48–4.69; P = 0.001) than those with low-monocyte count (Table 2).